Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Paris Mamikunian"'
Autor:
Gregg Mamikunian, Paris Mamikunian, Daniel Raines, Eugene A. Woltering, Catherine T. Anthony, Maria M. Chester, Anne E. Diebold
Publikováno v:
Pancreas. 41:508-511
ObjectiveProton pump inhibitors (PPIs) are used primarily to treat gastroesophageal reflux disease. Proton pump inhibitor–induced achlorhydria increases circulating gastrin and chromogranin A (CGA). Chromogranin is a widely used biomarker for the d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::343fb2aa6c6c4683db511ee765a44ffa
https://doi.org/10.1097/mpa.0b013e318243a0b6
https://doi.org/10.1097/mpa.0b013e318243a0b6
Autor:
Vay Liang W. Go, Joy Ardill, Gregg Mamikunian, Siegfried R. Krutzik, Thomas M. O'Dorisio, Aaron I. Vinik, Lee Armstrong, Paris Mamikunian, Eugene A. Woltering
Publikováno v:
Pancreas. 40(7)
International cooperative group trials require specific, sensitive biomarker assays that are validated between continents. Neurokinin A (NKA) has been shown to be a powerful independent predictor of a poor prognosis in well-differentiated midgut neur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ad16c7dbc83594e4be849158307ed7a
https://pubmed.ncbi.nlm.nih.gov/21926539
https://pubmed.ncbi.nlm.nih.gov/21926539
Autor:
Gregg Mamikunian, Vinik Ai, Ying Zhou, Jacky R. Seward, Paris Mamikunian, Vergilio A. Salvo, Gang Li, Vay Liang W. Go, Thomas M. O'Dorisio, Eugene A. Woltering, John Lyons
Publikováno v:
Pancreas. 37(1)
Octreotide is one of the most commonly used medications in the treatment of symptomatic neuroendocrine tumors (NETS). Traditionally, the vast majority of NETS patients receiving this medication have prompt and effective relief of their symptoms. We h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3cfde0a7885ae7fba8a9558b3f2f9f3
https://pubmed.ncbi.nlm.nih.gov/18815562
https://pubmed.ncbi.nlm.nih.gov/18815562
Autor:
Thomas M. O'Dorisio, Gregg Mamikunian, Aaron I. Vinik, Paris Mamikunian, Stanley Zietz, Seigfried R Krutzik, Etta J. Vinik, Eugene A. Woltering, Vay Liang W. Go
Publikováno v:
Pancreas. 31(4)
Octreotide long acting repeatable (LAR) is widely used for the control of symptoms of functional neuroendocrine tumors. At doses of 30 mg/mo, up to 40% of patients require subcutaneous octreotide "rescue" and up to 40% of patients are given more than
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62b1500c35c14a7bc168513b2a55fa72
https://pubmed.ncbi.nlm.nih.gov/16258376
https://pubmed.ncbi.nlm.nih.gov/16258376